Skip to main content
Equibles

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in CLLS — Cellectis S.A.

CIK 861177 NEW YORK, NY
Back to CLLS Full portfolio

Position in CLLS

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$7,934,643
-$2,141,581 QoQ
Shares Held
2,644,881
-16.8% QoQ
Ownership
2.63%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#3
of 27 holders
Holding Since
Jun 2024
8 quarters on record
Voting authority Sole 29% Shared 0% None 71%

Common Shares in CLLS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,443,898,601 across 206 Biotechnology names. CLLS ranks #49 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 3,086,683 $1,533,248,041
2 REGN
Regeneron Pharmaceuticals, Inc.
 716,560 $446,803,817
3 ALNY
Alnylam Pharmaceuticals, Inc.
 727,848 $219,104,078
4 INCY
Incyte Corp
 1,508,720 $171,028,494
5 RVMD
Revolution Medicines, Inc.
 912,335 $170,862,094
6 INSM
INSMED Inc
 1,335,071 $142,345,265
7 IONS
Ionis Pharmaceuticals Inc
 1,454,672 $115,340,938
8 MRNA
Moderna, Inc.
 1,521,849 $106,575,080

All Filings in CLLS

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $7,934,643 2,644,881
2026-03-31 $10,076,224 3,178,620
2025-12-31 $15,384,520 3,178,620
2025-06-30 $4,847,395 3,178,620
2025-03-31 $5,856,102 4,722,664
2024-12-31 $2,588,859 1,438,255
2024-09-30 $3,049,100 1,438,255
2024-06-30 $2,689,536 1,438,255